Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact

American Journal of Clinical Pathology

Volumn 123, Issue 6, 2005, Pages 874-878

  Asian, Deniz L ^a   Gulbahce, H Evin ^a   Pambuccian, Stefan E ^a   Manivel, J Carlos ^a   Jessurun, Jose ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Fairview University   (United States)

Author keywords

Carcinoid; Chromogranin; Cytokeratin; Immunohistochemistry; Ki 67; Lung; MIB 1; Neuroendocrine neoplasms; Small cell carcinoma; Synaptophysin

Indexed keywords

CHROMOGRANIN A; CYTOKERATIN; KI 67 ANTIGEN; SYNAPTOPHYSIN;

ARTICLE; ARTIFACT; CARCINOID; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG TUMOR; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PULMONARY NEUROENDOCRINE NEOPLASM; SMALL CELL CARCINOMA; TUMOR BIOPSY;

ARTIFACTS; BIOPSY; BRONCHOSCOPY; CARCINOID TUMOR; CARCINOMA, SMALL CELL; CHROMOGRANIN A; CHROMOGRANINS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOENZYME TECHNIQUES; KERATINS; KI-67 ANTIGEN; LUNG NEOPLASMS; SYNAPTOPHYSIN;

EID: 19644396286     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/QYV0-5VGE-GKUL-2RTT     Document Type: Article

References (30)

1. Fielder DB. Neuroendocrine tumors of the lung: recent developments in histopathology. Curr Opin Pulm Med. 2002;8:275-280.
2. Travis WD, Colby TV, Corrin B, et al. Histological Typing of Lung and Pleural Tumours. Berlin, Germany: World Health Organization; 1999. World Health Organization International Histological Classification of Tumours.
3. Azzopardi JG. Oat-cell carcinoma of the bronchus. J Pathol Bacteriol. 1959;78:513-519.
4. Davenport RD. Diagnostic value of crush artifact in cytologic specimens: occurrence in small cell carcinoma of the lung. Acta Cytol. 1990;34;502-504.
5. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest. 2003;123(1 suppl): 115S-128S.
6. Younossian AB, Brundler MA, Totsch M. Feasibility of the new WHO classification of pulmonary neuroendocrine tumours. Swiss Med Wkly. 2002;132:535-540.
7. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184-1197.
8. Franklin WA. Pathology of lung cancer. J Thorac Imaging. 2000;15:3-12.
9. Barbareschi M, Girlando S, Mauri FA, et al. Tumour suppressor gene products, proliferation, and differentiation markers in lung neuroendocrine neoplasms. J Pathol. 1992;166:343-350.
10. Rusch VW, Klimstra DS, Venkatraman ES. Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg. 1996;62:798-810.
11. Roncalli M, Doglioni C, Springall DR, et al. Abnormal p53 expression in lung neuroendocrine tumors: diagnostic and prognostic implications. Diagn Mol Pathol. 1992;1:129-135.
12. Gouyer V, Gazzeri S, Bolon I, et al. Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol 1998;18:188-196.
13. Brambilla E, Negouscu A, Gazzeri S, et al. Apoptosis-related factors p53, bcl12, and Bax in neuroendocrine lung tumors. Am J Pathol. 1996;149:1941-1952.
14. Onuki N, Wistuba, II, Travis WD, et al. Genetic changes in the spectrum of neuroendocrine lung tumors. Cancer. 1999;85:600-607.
15. Lin O, Olgac S, Green 1, et al. Immunohistochemical staining of cytologic smears with MIB-1 helps distinguish low-grade from high-grade neuroendocrine neoplasms. Am J Clin Pathol. 2003;120:209-216.
16. Arbiser ZK, Arbiser JL, Cohen C, et al. Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis. Mod Pathol 2001;14:1195-1199.
17. ' 17. Costes V, Marty-Ane C, Picot MC, et al. Typical and atypical bronchopulmonary carcinoid tumors: a clinicopathologic and Ki-67-labeling study. Hum Pathol. 1995;26:740-745.
18. Bohm J, Koch S, Gais P, et al. Prognostic value of MIB-1 in neuroendocrine tumours of the lung. J Pathol. 1996;178:402-409.
19. Kawai T, Suzuki M, Kono S, et al. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma: correlation with DNA flow cytometric analysis. Cancer. 1994;74:2468-2475.
20. Tungekar MF, Gatter KC, Dunnill MS, et al. Ki-67 immunostaining and survival in operable lung cancer. Histopathobgy. 1991;19:545-550.
21. Soomro IN, Whimster WE Growth fraction in lung tumours determined by Ki67 immunostaining and comparison with AgNOR scores. J Pathol. 1990;162:217-222.
22. Gatter KC, Dunnill MS, Gerdes J, et al. New approach to assessing lung tumours in man. J Clin Pathol. 1986;39:590-593.
23. Laitinen KL, Soini Y, Mattila J, et al. Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity. Cancer. 2000;88:1590-1598.
24. Hayashi Y, Fukayama M, Koike M, et al. Cell-cycle analysis detecting endogenous nuclear antigens: comparison with BrdU-in vivo labeling and an application to lung tumors. Acta Pathol Jpn. 1993;43:313-319.
25. Judkins AR, Roberts SA, LiVolsi VA. Utility of immunohistochemistry in the evaluation of necrotic thyroid tumors. Hum Pathol. 1993;30:1373-1376.
26. Pelstring RJ, Allred DC, Ester RJ, et al. Differential antigen preservation during tissue autolysis. Hum Pathol. 1991;22:237-241.
27. Norton AJ, Ramsay AD, Isaacson PG. Antigen preservation in infarcted lymphoid tissue: a novel approach to the infarcted lymph node using monoclonal antibodies effective in routinely processed tissues. Am J Surg Pathol. 1988;12:759-767.
28. Galazka K. Evaluation of the proliferative activity as an adjuvant helpful tool in the diagnosis of primary gastric lymphoma in gastrobiopsy. Pol J Pathol. 2001;52:205-209.
29. Kaufmann O, Georgi T, Dieteil M. Utility of 123C3 monoclonal antibody against CD56 (NCAM) for the diagnosis of small cell carcinomas on paraffin sections. Hum Pathol. 1997;28:1373-1378.
30. Mittal K. Utility of MIB-1 in evaluating cauterized cervical cone biopsy margins. Int J Gynecol Pathol. 1999;18:211-214.